Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis

American Journal of Respiratory Cell and Molecular Biology

Volumn 50, Issue 3, 2014, Pages 549-558

  Lambert, James A ^a,f   Raju, S Vamsee ^a   Tang, Li Ping ^a,e   McNicholas, Carmel M ^c   Li, Yao ^a,e   Courville, Clifford A ^a   Farris, Roopan F ^a,b   Coricor, George E ^f   Smoot, Lisa H ^a   Mazur, Marina M ^e   Dransfield, Mark T ^a,d   Bolger, Graeme B ^a,g   Rowe, Steven M ^a,b,c,d,e  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g University of Alabama at Birmingham   (United States)

Author keywords

Chronic obstructive pulmonary disease; Cigarette smoke; Cystic fibrosis transmembrane conductance regulator; Ion transport; Roflumilast

Indexed keywords

CIGARETTE SMOKE; CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORSKOLIN; IVACAFTOR; ROFLUMILAST; UNCLASSIFIED DRUG; WHOLE CIGARETTE SMOKE;

AIR; AIRWAY; AIRWAY SURFACE LIQUID; ANIMAL CELL; ANIMAL EXPERIMENT; ANION TRANSPORT; ARTICLE; BRONCHIAL EPITHELIAL CELL; BRONCHUS MUCOSA; CHRONIC BRONCHITIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIUM CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTESTINE; INTESTINE EPITHELIUM; INTESTINE FLUID; ION TRANSPORT; LUNG FLUID; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SECRETION (PROCESS); SMALL INTESTINE;

AMINOPHENOLS; AMINOPYRIDINES; ANIMALS; BENZAMIDES; BRONCHI; BRONCHITIS, CHRONIC; CELLS, CULTURED; CYCLIC AMP; CYCLOPROPANES; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; INTESTINAL SECRETIONS; INTESTINE, SMALL; MEMBRANE POTENTIALS; MICE; MUCOCILIARY CLEARANCE; PHOSPHODIESTERASE 4 INHIBITORS; QUINOLONES; SMOKE; SMOKING; TIME FACTORS;

EID: 84895532370     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0228OC     Document Type: Article

References (53)

1. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet 2003;362:1053-1061.
2. Sloane PA, Shastry S, Wilhelm A, Courville C, Tang LP, Backer K, Levin E, Raju SV, Li Y, Mazur M, et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS ONE 2012;7: e39809.
3. Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007;87:1047-1082.
4. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352: 1992-2001.
5. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-1015.
6. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
7. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with fev1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530-1535.
8. Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, Liao J, Zielenski J, Durie P. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006;173:1139-1144.
9. Kreindler JL, Jackson AD, Kemp PA, Bridges RJ, Danahay H. Inhibition of chloride secretion in human bronchial epithelial cells by cigarette smoke extract. Am J Physiol Lung Cell Mol Physiol 2005;288: L894-L902.
10. Clunes LA, Davies CM, Coakley RD, Aleksandrov AA, Henderson AG, Zeman KL, Worthington EN, Gentzsch M, Kreda SM, Cholon D, et al. Cigarette smoke exposure induces cftr internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 2012;26:533-545.
11. Dransfield MT, Wilhelm AM, Flanagan B, Courville C, Tidwell SL, Raju SV, Gaggar A, Steele C, Tang LP, Liu B, et al. Acquired CFTR dysfunction in the lower airways in COPD. Chest 2013;144:498-506.
12. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007;76:481-511.
13. Dent G, White SR, Tenor H, Bodtke K, Schudt C, Leff AR, Magnussen H, Rabe KF. Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm Pharmacol Ther 1998;11:47-56.
14. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, Heeke GV. Differential expression of Pde4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 2004;287:L332-L343.
15. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-694.
16. Cobb BR, Fan L, Kovacs TE, Sorscher EJ, Clancy JP. Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in calu-3 cells. Am J Respir Cell Mol Biol 2003;29:410-418.
17. Spina D. Pde4 inhibitors: current status. Br J Pharmacol 2008;155: 308-315.
18. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992-2001.
19. Sonawane ND, Hu J, Muanprasat C, Verkman AS. Luminally active, nonabsorbable cftr inhibitors as potential therapy to reduce intestinal fluid loss in cholera. FASEB J 2006;20:130-132.
20. Pyle LC, Ehrhardt A, Mitchell LH, Fan L, Ren A, Naren AP, Li Y, Clancy JP, Bolger GB, Sorscher EJ, et al. Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators. Am J Physiol Lung Cell Mol Physiol 2011; 301:L587-L597.
21. Raju SV, Jackson PL, Courville C, Sloane PA, Tang LP, Dransfield MT, Rowe SM. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator (CFTR) function. Am J Respir Crit Care Med (In press)
22. Hickman-Davis JM, McNicholas-Bevensee C, Davis IC, Ma HP, Davis GC, Bosworth CA, Matalon S. Reactive species mediate inhibition of alveolar type ii sodium transport during mycoplasma infection. Am J Respir Crit Care Med 2006;173:334-344.
23. Schramm S, Carre V, Scheffler JL, Aubriet F. Analysis of mainstream and sidestream cigarette smoke particulate matter by laser desorption mass spectrometry. Anal Chem 2011;83:133-142.
24. Clunes LA, Davies CM, Coakley RD, Aleksandrov AA, Henderson AG, Zeman KL, Worthington EN, Gentzsch M, Kreda SM, Cholon D, et al. Cigarette smoke exposure induces cftr internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 2012;26:533-545.
25. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67.
26. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, vx-770. Proc Natl Acad Sci USA 2009;106:18825-18830.
27. Zhang L, Button B, Gabriel SE, Burkett S, Yan Y, Skiadopoulos MH, Dang YL, Vogel LN, McKay T, Mengos A, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 2009;7: e1000155.
28. Innes AL, Woodruff PG, Ferrando RE, Donnelly S, Dolganov GM, Lazarus SC, Fahy JV. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006;130: 1102-1108.
29. Savitski AN, Mesaros C, Blair IA, Cohen NA, Kreindler JL. Secondhand smoke inhibits both Cl- and K1 conductances in normal human bronchial epithelial cells. Respir Res 2009;10:120.
30. Matsui H, Randell SH, Peretti SW, Davis CW, Boucher RC. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest 1998;102:1125-1131.
31. Di YP, Zhao J, Harper R. Cigarette smoke induces muc5ac protein expression through the activation of sp1. J Biol Chem 2012;287: 27948-27958.
32. Graeber SY, Zhou-Suckow Z, Schatterny J, Hirtz S, Boucher RC, Mall MA. Hypertonic saline is effective in the prevention and treatment of mucus obstruction but not airway inflammation in mice with chronic obstructive lung disease. Am J Respir Cell Mol Biol 2013;49: 410-417.
33. Milara J, Armengot M, Banuls P, Tenor H, Beume R, Artigues E, Cortijo J. Roflumilast n-oxide, a pde4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. Br J Pharmacol 2012;166:2243-2262.
34. Moran O. Model of the camp activation of chloride transport by CFTR channel and the mechanism of potentiators. J Theor Biol 2010;262: 73-79.
35. Barnes AP, Livera G, Huang P, Sun C, O'Neal WK, Conti M, Stutts MJ, Milgram SL. Phosphodiesterase 4d forms a camp diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem 2005; 280:7997-8003.
36. Lee JH, Richter W, Namkung W, Kim KH, Kim E, Conti M, Lee MG. Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. J Biol Chem 2007;282:10414-10422.
37. O'Grady SM, Jiang X, Maniak PJ, Birmachu W, Scribner LR, Bulbulian B, Gullikson GW. Cyclic AMP-dependent Cl secretion is regulated by multiple phosphodiesterase subtypes in human colonic epithelial cells. J Membr Biol 2002;185:137-144.
38. Liu S, Veilleux A, Zhang L, Young A, Kwok E, Laliberte F, Chung C, Tota MR, Dube D, Friesen RW, et al. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4d phosphodiesterase inhibitors. J Pharmacol Exp Ther 2005;314:846-854.
39. Page CP, Spina D. Selective pde inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 2012;12:275-286.
40. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A. Inhibition of tgf-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 2007;572:12-22.
41. Knudson AG Jr, Wayne L, Hallett WY. On the selective advantage of cystic fibrosis heterozygotes. Am J Hum Genet 1967;19:388-392.
42. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365:167-175.
43. Zhang W, Fujii N, Naren AP. Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas. Future Med Chem 2012;4:329-345.
44. Dransfield MT, Wilhelm AM, Flanagan B, Tidwell SL, Raju SV, Gaggar A, Steele C, Tang LP, Liu B, Rowe SM. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest 2013;144:498-506.
45. Eckford PD, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator vx-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem 2012;287:36639-36649.
46. Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA 2013;110:4404-4409.
47. Le Gars M, Descamps D, Roussel D, Saussereau E, Guillot L, Ruffin M, Tabary O, Hong SS, Boulanger P, Paulais M, et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med 2013;187:170-179.
48. Bodas M, Min T, Mazur S, Vij N. Critical modifier role of membranecystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema. J Immunol 2011; 186:602-613.
49. Bradbury NA, Jilling T, Berta G, Sorscher EJ, Bridges RJ, Kirk KL. Regulation of plasma membrane recycling by cftr. Science 1992;256:530-532.
50. Mata M, Sarria B, Buenestado A, Cortijo J, Cerda M, Morcillo EJ. Phosphodiesterase 4 inhibition decreases muc5ac expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005;60:144-152.
51. Di Benedetto G, Manara-Shediac FS, Mehta A. Effect of cyclic amp on ciliary activity of human respiratory epithelium. Eur Respir J 1991;4: 789-795.
52. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappab, p38 mitogen-activated protein kinase, and c-jun nh2-terminal kinase activation. J Pharmacol Exp Ther 2005;315:1188-1195.
53. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel pde4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-279.